By increasing HSF1 protein levels, proteasome inhibitors (PSIs) such as MG132 and the anti-tumor drug bortezomib could promote the generation of CD69+ Tregs, thus offering a practical approach to generate potent iTregs for the treatment of colitis and probably other autoimmune diseases. The gene discussed is CD69; the disease is autoimmune disease.